Targeting the endocannabinoid system with microbial interventions to improve gut integrity

Jansma, Jack; Brinkman, Fleur; Hemert, Saskia van; Aidy, Sahar El

doi:10.1016/j.pnpbp.2020.110169

Cited by 28 publications

(12 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, gut microbiota continuously excretes bioactive molecules in the bowel lumen and some of them may translocate into the circulation and further make an influence on the metabolic process as specific ligands [ 8 ]. During the process, intestinal integrity plays an important role by blocking the harmful bacterial metabolites transferred into the circulation [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review

et al. 2021

View full text Add to dashboard Cite

Metabolic diseases are serious threats to public health and related to gut microbiota. Probiotics, prebiotics, synbiotics, and postbiotics (PPSP) are powerful regulators of gut microbiota, thus possessing prospects for preventing metabolic diseases. Therefore, the effects and mechanisms of PPSP on metabolic diseases targeting gut microbiota are worth discussing and clarifying. Generally, PPSP benefit metabolic diseases management, especially obesity and type 2 diabetes mellitus. The underlying gut microbial-related mechanisms are mainly the modulation of gut microbiota composition, regulation of gut microbial metabolites, and improvement of intestinal barrier function. Moreover, clinical trials showed the benefits of PPSP on patients with metabolic diseases, while the clinical strategies for gestational diabetes mellitus, optimal formula of synbiotics and health benefits of postbiotics need further study. This review fully summarizes the relationship between probiotics, prebiotics, synbiotics, postbiotics, and metabolic diseases, presents promising results and the one in dispute, and especially attention is paid to illustrates potential mechanisms and clinical effects, which could contribute to the next research and development of PPSP.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Accumulating evidence suggests the pivotal role exerted by the eCBome in the pathophysiology of GI disorders [142]. In particular, several ligands and receptors of the eC-Bome are involved in the regulation of GI motility and secretion, intestinal inflammation and mucosal barrier permeability, as recently reviewed elsewhere [142][143][144]. In this paragraph, description will be limited to the involvement of the eCBome in the so-called "leaky gut", i.e., the impairment of the gut barrier which is associated not only to different enteropathies (including IBD), but also some of the metabolic disorders we have focused on in the above paragraph, e.g., obesity and diabetes mellitus.…”

Section: The Endocannabinoidome and Intestinal Permeability Barriermentioning

confidence: 97%

Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional Viewpoint

Moriello

Marzo

Petrosino

2022

Animals

View full text Add to dashboard Cite

There is growing evidence that perturbation of the gut microbiome, known as “dysbiosis”, is associated with the pathogenesis of human and veterinary diseases that are not restricted to the gastrointestinal tract. In this regard, recent studies have demonstrated that dysbiosis is linked to the pathogenesis of central neuroinflammatory disorders, supporting the existence of the so-called microbiome-gut-brain axis. The endocannabinoid system is a recently recognized lipid signaling system and termed endocannabinoidome monitoring a variety of body responses. Accumulating evidence demonstrates that a profound link exists between the gut microbiome and the endocannabinoidome, with mutual interactions controlling intestinal homeostasis, energy metabolism and neuroinflammatory responses during physiological conditions. In the present review, we summarize the latest data on the microbiome-endocannabinoidome mutual link in health and disease, focalizing the attention on gut dysbiosis and/or altered endocannabinoidome tone that may distort the bidirectional crosstalk between these two complex systems, thus leading to gastrointestinal and metabolic diseases (e.g., idiopathic inflammation, chronic enteropathies and obesity) as well as neuroinflammatory disorders (e.g., neuropathic pain and depression). We also briefly discuss the novel possible dietary interventions based not only on probiotics and/or prebiotics, but also, and most importantly, on endocannabinoid-like modulators (e.g., palmitoylethanolamide) for intestinal health and beyond.

show abstract

“…In particular, primarily by leading the release of pro-inflammatory cytokines and other neurotrophic factors from the mesenteric lymph nodes which albeit to BBB disruption, LPS favors the infiltration of leukocytes into the CNS and finally promotes the development of neuroinflammation state. Therefore, targeting the eCB system in the gut can modulate the integrity of intestinal barrier [ 176 ]. Furthermore, leaky gut and endotoxemia are characteristic features of obesity [ 177 ] that is considered a risk factor for AD.…”

Section: The Ecbome As the “Hidden” Player Between The Gut And The Brain In Admentioning

confidence: 99%

The Endocannabinoid System: A Bridge between Alzheimer’s Disease and Gut Microbiota

Bisogno

Lauritano

Piscitelli

2021

Life

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurodegenerative disease that progresses from mild cognitive impairment to severe dementia over time. The main clinical hallmarks of the disease (e.g., beta-amyloid plaques and neurofibrillary tangles) begin during preclinical AD when cognitive deficits are not yet apparent. Hence, a more profound understanding of AD pathogenesis is needed to develop new therapeutic strategies. In this context, the endocannabinoid (eCB) system and the gut microbiome are increasingly emerging as important players in maintaining the general homeostasis and the health status of the host. However, their interaction has come to light just recently with gut microbiota regulating the eCB tone at both receptor and enzyme levels in intestinal and adipose tissues. Importantly, eCB system and gut microbiome, have been suggested to play a role in AD in both animal and human studies. Therefore, the microbiome gut-brain axis and the eCB system are potential common denominators in the AD physiopathology. Hence, the aim of this review is to provide a general overview on the role of both the eCB system and the microbiome gut-brain axis in AD and to suggest possible mechanisms that underlie the potential interplay of these two systems.

show abstract

Targeting the endocannabinoid system with microbial interventions to improve gut integrity

Cited by 28 publications

References 78 publications

Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review

Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review

Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional Viewpoint

The Endocannabinoid System: A Bridge between Alzheimer’s Disease and Gut Microbiota

Contact Info

Product

Resources

About